Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Nov;66(5):850–855. doi: 10.1038/bjc.1992.372

Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.

B Biesma 1, P H Willemse 1, N H Mulder 1, R C Verschueren 1, I P Kema 1, H W de Bruijn 1, P E Postmus 1, D T Sleijfer 1, E G de Vries 1
PMCID: PMC1977979  PMID: 1384643

Abstract

Malignant carcinoid tumours, islet cell tumours and medullary carcinomas of the thyroid are tumours with similar clinical features. In patients with unresectable or metastatic tumours leukocyte interferon (IFN) and recombinant human (rh) IFN have demonstrated efficacy. Twenty-four evaluable patients with progressive tumours were treated with 2.5 megaunits rh IFN alpha-2b, administered once daily subcutaneously, for a median duration of 7 months (range 0.5-37+). Two carcinoid patients demonstrated a response in tumour size, 80% showed stable disease (SD). Sixty percent of the carcinoid patients with elevated urinary 5-hydroxyindoleacetic (5-HIAA) levels reached a biochemical partial response of the urinary 5-HIAA levels (median duration 13.5 months). In the patients with an islet cell or medullary tumour and an elevated tumour marker, the marker did not further increase. Of the 12 carcinoid patients evaluable for a symptomatic response, ten (83%) experienced a relieve of symptoms. IFN alpha-2b dose reduction or discontinuation due to toxicity was necessary in three and ten patients, respectively. No neutralising IFN alpha-2b antibodies developed despite prolonged treatment. In conclusion, IFN alpha-2b had a beneficial effect in patients with progressive tumours, while long-term IFN alpha-2b treatment did not augment neutralising antibodies. In view of the IFN alpha-2b-related toxicity, administration of IFN alpha-2b on alternating days may be preferable.

Full text

PDF
850

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. V., Bloom S. R. Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. Lancet. 1987 Jan 10;1(8524):97–97. doi: 10.1016/s0140-6736(87)91927-1. [DOI] [PubMed] [Google Scholar]
  2. Andersson T., Wilander E., Eriksson B., Lindgren P. G., Oberg K. Effects of interferon on tumor tissue content in liver metastases of human carcinoid tumors. Cancer Res. 1990 Jun 1;50(11):3413–3415. [PubMed] [Google Scholar]
  3. Eriksson B., Oberg K., Alm G., Karlsson A., Lundqvist G., Andersson T., Wilander E., Wide L. Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. Lancet. 1986 Dec 6;2(8519):1307–1309. doi: 10.1016/s0140-6736(86)91435-2. [DOI] [PubMed] [Google Scholar]
  4. Eriksson B., Oberg K., Alm G., Karlsson A., Lundqvist G., Magnusson A., Wide L., Wilander E. Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon. Cancer Treat Rep. 1987 Jan;71(1):31–37. [PubMed] [Google Scholar]
  5. Feldman J. M., Butler S. S., Chapman B. A., Bivens C. E. Catecholamine metabolism in the carcinoid syndrome. Clin Chim Acta. 1974 Feb 28;51(1):75–81. doi: 10.1016/0009-8981(74)90063-1. [DOI] [PubMed] [Google Scholar]
  6. Feldman J. M. Urinary serotonin in the diagnosis of carcinoid tumors. Clin Chem. 1986 May;32(5):840–844. [PubMed] [Google Scholar]
  7. Gröhn P., Kumpulainen E., Jakobsson M. Response of medullary thyroid cancer to low-dose alpha-interferon therapy. Acta Oncol. 1990;29(7):950–951. doi: 10.3109/02841869009096398. [DOI] [PubMed] [Google Scholar]
  8. Hanssen L. E., Schrumpf E., Kolbenstvedt A. N., Tausjø J., Dolva L. O. Treatment of malignant metastatic midgut carcinoid tumours with recombinant human alpha2b interferon with or without prior hepatic artery embolization. Scand J Gastroenterol. 1989 Sep;24(7):787–795. doi: 10.3109/00365528909089215. [DOI] [PubMed] [Google Scholar]
  9. Kema I. P., de Vries E. G., Schellings A. M., Postmus P. E., Muskiet F. A. Improved diagnosis of carcinoid tumors by measurement of platelet serotonin. Clin Chem. 1992 Apr;38(4):534–540. [PubMed] [Google Scholar]
  10. Kessinger A., Foley J. F., Lemon H. M. Therapy of malignant APUD cell tumors. Effectiveness of DTIC. Cancer. 1983 Mar 1;51(5):790–794. doi: 10.1002/1097-0142(19830301)51:5<790::aid-cncr2820510507>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  11. Keyzer J. J., de Monchy J. G., van Doormaal J. J., van Voorst Vader P. C. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med. 1983 Dec 29;309(26):1603–1605. doi: 10.1056/NEJM198312293092603. [DOI] [PubMed] [Google Scholar]
  12. Kvols L. K. Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy. Am J Med. 1986 Dec 22;81(6B):49–55. doi: 10.1016/0002-9343(86)90584-x. [DOI] [PubMed] [Google Scholar]
  13. Kvols L. K., Moertel C. G., O'Connell M. J., Schutt A. J., Rubin J., Hahn R. G. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986 Sep 11;315(11):663–666. doi: 10.1056/NEJM198609113151102. [DOI] [PubMed] [Google Scholar]
  14. Kwarts E., Kwarts J., Rutgers H. A simple paired-ion liquid chromatography assay for serotonin in cerebrospinal fluid, platelet-rich plasma, serum and urine. Ann Clin Biochem. 1984 Sep;21(Pt 5):425–429. doi: 10.1177/000456328402100515. [DOI] [PubMed] [Google Scholar]
  15. Moertel C. G., Hanley J. A., Johnson L. A. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980 Nov 20;303(21):1189–1194. doi: 10.1056/NEJM198011203032101. [DOI] [PubMed] [Google Scholar]
  16. Moertel C. G. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol. 1987 Oct;5(10):1502–1522. doi: 10.1200/JCO.1987.5.10.1502. [DOI] [PubMed] [Google Scholar]
  17. Moertel C. G., Lefkopoulo M., Lipsitz S., Hahn R. G., Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992 Feb 20;326(8):519–523. doi: 10.1056/NEJM199202203260804. [DOI] [PubMed] [Google Scholar]
  18. Moertel C. G., Rubin J., Kvols L. K. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol. 1989 Jul;7(7):865–868. doi: 10.1200/JCO.1989.7.7.865. [DOI] [PubMed] [Google Scholar]
  19. Muskiet F. A., Stratingh M. C., Stob G. J., Wolthers B. G. Simultaneous determination of the four major catecholamine metabolites and estimation of a serotonin metabolite in urine by capillary gas chromatography of their tert-butyldimethylsilyl derivatives. Clin Chem. 1981 Feb;27(2):223–227. [PubMed] [Google Scholar]
  20. Muskiet F. A., Thomasson C. G., Gerding A. M., Fremouw-Ottevangers D. C., Nagel G. T., Wolthers B. G. Determination of catecholamines and their 3-O-methylated metabolites in urine by mass fragmentography with use of deuterated internal standards. Clin Chem. 1979 Mar;25(3):453–460. [PubMed] [Google Scholar]
  21. Oberg K., Alm G., Magnusson A., Lundqvist G., Theodorsson E., Wide L., Wilander E. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst. 1989 Apr 5;81(7):531–535. doi: 10.1093/jnci/81.7.531. [DOI] [PubMed] [Google Scholar]
  22. Oberg K., Funa K., Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med. 1983 Jul 21;309(3):129–133. doi: 10.1056/NEJM198307213090301. [DOI] [PubMed] [Google Scholar]
  23. Oberg K., Norheim I., Alm G. Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon. Eur J Cancer Clin Oncol. 1989 Oct;25(10):1475–1479. doi: 10.1016/0277-5379(89)90107-7. [DOI] [PubMed] [Google Scholar]
  24. Oberg K., Norheim I., Lind E., Alm G., Lundqvist G., Wide L., Jonsdottir B., Magnusson A., Wilander E. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results. Cancer Treat Rep. 1986 Nov;70(11):1297–1304. [PubMed] [Google Scholar]
  25. PERNOW B., WALDENSTROM J. Determination of 5-hydroxytryptamine, 5-hydroxyindole acetic acid and histamine in thirty-three cases of carcinoid tumor (argentaffinoma). Am J Med. 1957 Jul;23(1):16–25. doi: 10.1016/0002-9343(57)90354-6. [DOI] [PubMed] [Google Scholar]
  26. Pearse A. G. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem. 1969 May;17(5):303–313. doi: 10.1177/17.5.303. [DOI] [PubMed] [Google Scholar]
  27. Prinz R. A., Bermes E. W., Jr, Kimmel J. R., Marangos P. J. Serum markers for pancreatic islet cell and intestinal carcinoid tumors: a comparison of neuron-specific enolase, beta-human chorionic gonadotropin and pancreatic polypeptide. Surgery. 1983 Dec;94(6):1019–1023. [PubMed] [Google Scholar]
  28. Prinz R. A., Marangos P. J. Serum neuron-specific enolase: a serum marker for nonfunctioning pancreatic islet cell carcinoma. Am J Surg. 1983 Jan;145(1):77–81. doi: 10.1016/0002-9610(83)90170-8. [DOI] [PubMed] [Google Scholar]
  29. Prinz R. A., Marangos P. J. Use of neuron-specific enolase as a serum marker for neuroendocrine neoplasms. Surgery. 1982 Nov;92(5):887–889. [PubMed] [Google Scholar]
  30. Roberts L. J., 2nd, Marney S. R., Jr, Oates J. A. Blockade of the flush associated with metastatic gastric carcinoid by combined histamine H1 and H2 receptor antagonists. Evidence for an important role of H2 receptors in human vasculature. N Engl J Med. 1979 Feb 1;300(5):236–238. doi: 10.1056/NEJM197902013000506. [DOI] [PubMed] [Google Scholar]
  31. Rosano T. G., Meola J. M., Swift T. A. Liquid-chromatographic determination of urinary 5-hydroxy-3-indoleacetic acid, with fluorescence detection. Clin Chem. 1982 Jan;28(1):207–208. [PubMed] [Google Scholar]
  32. Ross C., Hansen M. B., Schyberg T., Berg K. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Clin Exp Immunol. 1990 Oct;82(1):57–62. doi: 10.1111/j.1365-2249.1990.tb05403.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Smith D. B., Scarffe J. H., Wagstaff J., Johnston R. J. Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor. Cancer Treat Rep. 1987 Dec;71(12):1265–1266. [PubMed] [Google Scholar]
  34. Spiegel R. J., Spicehandler J. R., Jacobs S. L., Oden E. M. Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A). Am J Med. 1986 Feb;80(2):223–228. doi: 10.1016/0002-9343(86)90013-6. [DOI] [PubMed] [Google Scholar]
  35. Veenhof C. H., de Wit R., Taal B. G., Dirix L. Y., Wagstaff J., Hensen A., Huldij A. C., Bakker P. J. A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour. Eur J Cancer. 1992;28(1):75–78. doi: 10.1016/0959-8049(92)90389-j. [DOI] [PubMed] [Google Scholar]
  36. Vinik A. I., Thompson N., Eckhauser F., Moattari A. R. Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management. Acta Oncol. 1989;28(3):389–402. doi: 10.3109/02841868909111212. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES